SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001341004-16-001444
Filing Date
2016-05-24
Accepted
2016-05-24 17:08:04
Documents
13
Effectiveness Date
2016-05-24

Document Format Files

Seq Description Document Type Size
1 DEFA14A defa14a.htm DEFA14A 120554
2 defa14a1.jpg GRAPHIC 22415
3 defa14a2.jpg GRAPHIC 17980
4 defa14a3.jpg GRAPHIC 17980
5 defa14a4.jpg GRAPHIC 17980
6 defa14a5.jpg GRAPHIC 17980
7 defa14a6.jpg GRAPHIC 26134
8 defa14a7.jpg GRAPHIC 46484
9 defa14a8.jpg GRAPHIC 17980
10 defa14a9.jpg GRAPHIC 20129
11 defa14a10.jpg GRAPHIC 29957
12 defa14a11.jpg GRAPHIC 17980
13 defa14a12.jpg GRAPHIC 17980
  Complete submission text file 0001341004-16-001444.txt   496273
Mailing Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8
Business Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8 514-744-6792
Valeant Pharmaceuticals International, Inc. (Filer) CIK: 0000885590 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-14956 | Film No.: 161672584
SIC: 2834 Pharmaceutical Preparations